Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P27694
UPID:
RFA1_HUMAN
Alternative names:
Replication factor A protein 1; Single-stranded DNA-binding protein
Alternative UPACC:
P27694; A8K0Y9; Q59ES9
Background:
Replication protein A 70 kDa DNA-binding subunit, also known as Replication factor A protein 1, plays a crucial role in DNA replication and repair. It stabilizes single-stranded DNA intermediates, recruits proteins for DNA metabolism, and is pivotal in DNA damage response, including nucleotide excision repair and telomere maintenance.
Therapeutic significance:
Given its essential role in telomere maintenance and response to DNA damage, understanding Replication protein A could lead to breakthroughs in treating Pulmonary fibrosis and bone marrow failure, telomere-related diseases, by targeting the underlying genetic variants.